Basic Information
| LncRNA/CircRNA Name | HCP5 |
| Synonyms | NA |
| Region | GRCh38_6:31400702-31477506 |
| Ensemble | ENSG00000206337 |
| Refseq | NR_040662 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Oxaliplatin,5-Fu | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP etc. |
| Sample | GC tissues and adjacent normal tissue,cell lines(AGS, MKN45, 293T) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA HCP5 drove FAO through miR-3619-5p/AMPK/PGC1?/CEBPB axis to promote stemness and chemo-resistance of GC, indicating that targeting HCP5 was a novel approach to enhancing the efficacy of chemotherapy in GC. |
| Pubmed ID | 32300102 |
| Year | 2020 |
| Title | MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1?/CEBPB axis to promote stemness and chemo-resistance of gastric cancer |
External Links
| Links for HCP5 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |